Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)

This study has been completed.
Sponsor:
Information provided by:
Ministry of Science and Higher Education, Poland
ClinicalTrials.gov Identifier:
NCT00375063
First received: September 11, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted

September 11, 2006
September 11, 2006
January 2001
Not Provided
  • LV function assessed by 2D echocardiography
  • exercise tolerance measured with ECG treadmill stress testing
  • angina severity according to CCS classification 12 months after the index intervention
Same as current
No Changes Posted
  • 30 day and one year major adverse events (MAE)
  • 30 day and one year major acute cardiovascular events (MACE)
  • length of hospitalization
  • one year and total survival and freedom from MACE
  • one year target vessel failure (TVF).
Same as current
Not Provided
Not Provided
 
Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)
Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery

Unprotected left main coronary artery (ULMCA) stenting, offering restoration of a native flow to left coronary artery, is the subject of intense investigations as a potential alternative to bypass surgery. The purpose of the study is to compare the short and long term results of unprotected left main stenting with coronary artery bypass surgery.

The natural history and the results of pharmacological treatment in patients with severe narrowing of left main coronary artery show very poor prognosis (5 year survival less than 50%).

There is general agreement that surgical treatment improves 5 year survival in patients with left main coronary artery obstruction 3, however long term survival rate (15 year follow-up) is low in both groups (37% and 27% respectively in surgical and medical group). Median survival was longer in surgical group in general population (13.3 vs 6.6 years) , but there was no significant difference in patients with normal LV ejection fraction (14.7 vs 15 years).

With the advent of coronary stenting encouraging results were reported by several authors. There was high success rate 98-100% for elective procedures and in these series the mortality (for protected and non-protected left main) ranged from 0 to 3.4 %, and 6 month event free survival rate was 70-80%. Restenosis rate in stented LM varied from 10-22% for proximal LM to 40% for distal LM. Final minimal luminal area >=7mm2 post procedure, assessed by IVUS, predicted low restenosis rate of 7%, while the area below <7mm2 was connected with restenosis of 50%. Our and other experience showed that left main in-stent restenosis can be treated successfully with another percutaneous intervention (including endarterectomy and balloon angioplasty) as well as by surgical revascularization.

Six and 12-month survival rate depended on the LV function. Patients with LVEF>40% had in-hospital event free survival of 98% and 9-month event free survival of 86%, whereas patients with LVEF <40% had in-hospital and 9 month event-free survival of 67 and 22% respectively. Additionally, in patients presented with acute myocardial infarction or bail-out procedures, early and late results of LM stenting were not as good as for elective cases.

Our previously presented promising results of left main stenting is mainly related to proper technique of LM stenting (short inflations within LM, careful guiding catheter manipulation, stent selection), as well as very cautiously designed follow-up (every month visit for first six month, routine coronary angiography within 3-6 months after procedure). This initial experience gives us the backgrounds for a larger prospective randomized trial comparing elective surgical revascularisation and percutaneous intervention in patients with LM coronary artery disease. It is our impression that design and the delivery system of the new generation stent is uniquely suited to safely treat this difficult subset of patients. At the present time we would limit the study to the discrete lesions in proximal (ostial and mid) left main with reference luminal diameter >=3 mm. Based on published results of stenting under IVUS examination for such a lesion we estimate the restenosis rate to be well below 10%. As we expect, the survival and complication rate within one year in both group will be similar. Therefore our main concern is weather both treatment strategies will offer the same prevention of LV function, as well as improvement of functional capacity and coronary reserve in both groups in a period of 2-3 years.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Coronary Artery Stenosis
  • Myocardial Revascularization
  • Myocardial Ischemia
  • Procedure: Percutaneous Coronary Intervention
  • Procedure: Coronary Artery Bypass Grafting
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
130
December 2005
Not Provided

Inclusion Criteria:

  • The patients' age 18 to 80
  • Significant LM stenosis (>50%)
  • The target vessel reference diameter 2.5mm.
  • Concomitant multivessel disease suitable for PCI is allowed.
  • The patient is an acceptable candidate for coronary artery bypass surgery.
  • The patient agreement for 6 month follow-up cardiac catheterization, which will include left ventricular angiogram.
  • The patient written informed consent.

Exclusion Criteria:

  • An allergy or contraindication to aspirin, ticlopidine or Clopidogrel.
  • Presence of diffuse, significant (>++) calcifications in LM
  • Left ventricular ejection fraction < 35%
  • History of bleeding diathesis or coagulopathy.
  • Any previous PCI or CABG surgery
  • Acute MI within 48 hours, cardiogenic shock.
  • Bail-out stenting of dissected LM during complicated PCI.
  • The patient suffered a stroke or transient ischemic neurological attack (TIA) within 3 months.
  • Chronic renal insufficiency.
  • Positive pregnancy test.
  • Any disease that may shorten the life expectancy of the patient.
  • The patient is currently participating in another research study.
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Poland
 
NCT00375063
6 P05B 132 21
Not Provided
Not Provided
Ministry of Science and Higher Education, Poland
Not Provided
Principal Investigator: Pawel E Buszman, Prof Silesian Medical School, Poland
Principal Investigator: Stefan R Kiesz, Prof 2San Antonio Endovascular and Heart Institute and University of Texas Health Science Center at San Antonio, Tx, USA,
Ministry of Science and Higher Education, Poland
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP